Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences
September 06 2016 - 7:00AM
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage
biopharmaceutical company focused on developing entinostat and
SNDX-6352 in multiple cancer indications, today announced its
planned participation in four upcoming investor conferences. The
details for the four conferences are:
- The Citi 11th Annual Biotech Conference at the Mandarin
Oriental Hotel in Boston, Massachusetts on September 8,
2016. Briggs W. Morrison, M.D., Chief Executive Officer of
Syndax, will participate in a panel titled “Developing Cancer
Therapeutics in 2016” at 8:00 am EDT.
- The Morgan Stanley Global Healthcare Conference at the
Grand Hyatt New York in New York City on September 12,
2016. Briggs W. Morrison, M.D., Chief Executive Officer of
Syndax, and Michael A. Metzger, President and Chief Operating
Officer of Syndax, will participate in an analyst led fireside chat
at 10:30 am EDT.
- The Rodman & Renshaw 18th Annual Global Investment
Conference at the Lotte New York Palace Hotel in New York City on
September 13, 2016. Briggs W. Morrison, M.D., Chief
Executive Officer of Syndax, will make a presentation at 3:00 pm
EDT.
- The 2nd Annual Ladenburg Thalmann 2016 Healthcare
Conference at the Sofitel New York in New York City on September
27, 2016. Briggs W. Morrison, M.D., Chief Executive
Officer of Syndax, will make a presentation at 2:30 pm EDT.
A live webcast of these presentations can be accessed from the
Investor section of the Company’s website at www.syndax.com, where
a replay of the events will also be available for a limited
time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on
developing an innovative pipeline of combination therapies in
multiple cancer indications. Our lead product candidate,
entinostat, which was granted Breakthrough Therapy designation by
the FDA following positive results from our Phase 2b clinical
trial, ENCORE 301, is currently being evaluated in a Phase 3
clinical trial for advanced hormone receptor positive breast
cancer. Syndax is developing entinostat, which has direct effects
on both cancer cells and immune regulatory cells, and SNDX-6352, an
anti-CSF-1R monoclonal antibody, to potentially enhance the body’s
immune response on tumors that have shown sensitivity to
immunotherapy. Entinostat is being evaluated as a combination
therapeutic in Phase 1b/2 clinical trials with Merck & Co.,
Inc. for non-small cell lung cancer and melanoma, with Genentech,
Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt,
Germany, for ovarian cancer. SNDX-6352 is expected to begin
clinical trials during the fourth quarter of 2016 and to be
developed to treat a variety of cancers. For more information on
Syndax, please visit www.syndax.com.
Syndax’s Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend,” “believe” and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax’s expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, the timing of the clinical development of
SNDX-6352 and the potential use of SNDX-6352 to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results, including unexpected
safety or efficacy data observed during preclinical or clinical
studies, clinical trial site activation or enrollment rates that
are lower than expected, changes in expected or existing
competition, changes in the regulatory environment, failure of
Syndax’s collaborators to support or advance collaborations or
product candidates and unexpected litigation or other disputes.
Other factors that may cause Syndax’s actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in Syndax’s filings with the U.S.
Securities and Exchange Commission, including the “Risk Factors”
sections contained therein. Except as required by law, Syndax
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Investor and Media Contacts
Barbara Ryan
bryan@syndax.com
(646) 690-7639
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Sep 2023 to Sep 2024